Vertex is paying nine figures to get its hands on CRISPR Therapeutics’ gene editing technology in a bid to make a third approach for type 1 diabetes.
The biotech said Monday morning that it is paying $100 million upfront to nab non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 gene editing technology. The goal, according to Vertex, is to move forward with preclinical development of a hypoimmune gene-edited cell therapy for type 1 diabetes.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,